| scholarly article | Q13442814 |
| P50 | author | Richard A. Larson | Q41899936 |
| Koen van Besien | Q43263315 | ||
| P2093 | author name string | Lucy A Godley | |
| Masha Kocherginsky | |||
| Michael R Bishop | |||
| Hongtao Liu | |||
| Wendy Stock | |||
| Andrew S Artz | |||
| Justin Kline | |||
| Lori S Muffly | |||
| Olatoyosi M Odenike | |||
| Quynh Chu | |||
| P2860 | cites work | Predictors of early death risk in older patients treated with first-line chemotherapy for cancer | Q48696372 |
| The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire | Q52101368 | ||
| Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project | Q53566418 | ||
| Progress in Development of the Index of ADL | Q56004802 | ||
| Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation | Q59315420 | ||
| Assessment of older people: self-maintaining and instrumental activities of daily living | Q66829682 | ||
| Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly | Q77769291 | ||
| Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) | Q79233975 | ||
| Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation | Q81079571 | ||
| Comorbidity and beyond: pre-transplant clinical assessment | Q81148873 | ||
| Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia | Q82236404 | ||
| Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT | Q24685958 | ||
| Frailty in older adults: evidence for a phenotype | Q28205094 | ||
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation | Q31828080 | ||
| Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up | Q33627703 | ||
| Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome | Q33813439 | ||
| Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale | Q34425278 | ||
| Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401 | Q34879258 | ||
| Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes | Q35142616 | ||
| Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies | Q35554703 | ||
| Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions | Q35608181 | ||
| Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive diseas | Q35770722 | ||
| Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). | Q36220834 | ||
| Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. | Q36643271 | ||
| Survival for older patients with acute myeloid leukemia: a population-based study | Q36662052 | ||
| Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study | Q36760924 | ||
| Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia | Q36873270 | ||
| Predicting 10-Year Mortality for Older Adults | Q37140181 | ||
| Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation | Q37157282 | ||
| Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score | Q39688507 | ||
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
| Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons | Q43463791 | ||
| Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group | Q44026953 | ||
| Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients | Q45933706 | ||
| Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study | Q45978553 | ||
| Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation | Q46724769 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1373-1379 | |
| P577 | publication date | 2014-05-09 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients | |
| P478 | volume | 99 |
| Q91724565 | A general practitioner's guide to hematopoietic stem-cell transplantation |
| Q26740584 | Acute myeloid leukemia in the older adults |
| Q39013605 | Aging: Treating the Older Patient |
| Q55515367 | Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. |
| Q38777460 | Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. |
| Q64109318 | Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study |
| Q48568744 | Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
| Q99604302 | Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age |
| Q30240259 | Biologic vs physiologic age in the transplant candidate. |
| Q64911398 | Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly. |
| Q60921241 | Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults |
| Q36615092 | Cardiovascular Complications of Hematopoietic Stem Cell Transplantation |
| Q36543682 | Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age |
| Q57301977 | Early mortality and survival in older adults with acute myeloid leukemia |
| Q92942038 | Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation - a single institution pilot study |
| Q100316285 | Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients |
| Q55360943 | Frailty in Hematologic Malignancy. |
| Q47869630 | Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment? |
| Q33766984 | From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation |
| Q60685780 | Geriatric Assessment in Older Patients with Acute Myeloid Leukemia |
| Q50058648 | Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis |
| Q87455036 | Getting fit for allogeneic hematopoietic cell transplantation |
| Q93160703 | Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70 |
| Q57288448 | Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns |
| Q92500556 | Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients |
| Q54277744 | Hematopoietic cell transplantation in older adults: deciding or decision-making? |
| Q99204490 | How to select older patients with acute myeloid leukemia fit for intensive treatment? |
| Q93023578 | Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies |
| Q97418351 | Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice |
| Q40859434 | Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. |
| Q52767299 | Initial therapy for acute myeloid leukemia in older patients: principles of care. |
| Q92904596 | Integrating Assessment of Sarcopenia into Decision-making for Allogeneic Hematopoietic Cell Transplantation: Ready for Prime Time? |
| Q64119387 | Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia |
| Q39093776 | Motivation and mortality in older women with early stage breast cancer: A longitudinal study with ten years of follow-up |
| Q35920698 | Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation |
| Q94600301 | Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients |
| Q38651372 | Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly |
| Q50104198 | Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia |
| Q47146837 | Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions |
| Q91829180 | Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission |
| Q88446410 | Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis |
| Q89485899 | Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables |
| Q38287009 | Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment |
| Q36447635 | Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902) |
| Q38581200 | Peripheral blood stem cell mobilization and collection from elderly patients and elderly healthy donor |
| Q96817610 | Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation |
| Q98471396 | Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia |
| Q64113105 | Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis |
| Q52663530 | Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience. |
| Q38604903 | Process of allogeneic hematopoietic cell transplantation decision making for older adults |
| Q35882830 | Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study |
| Q38488058 | Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation |
| Q48229580 | Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. |
| Q38881049 | Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma |
| Q64092506 | State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 |
| Q49987424 | The management and treatment of acute leukemias in the elderly population |
| Q33573495 | The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes |
| Q92447535 | Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness |
| Q30240238 | Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens |
| Q38858092 | Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation |
| Q58049269 | Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant |
Search more.